Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1701724

	registered interest
	date	17/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Incontinence: Products
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will make a comparative assessment of the cost to the NHS of different kinds of absorbent continence products based on the (a) item price and (b) patient experience and outcome including (i) whole system cost, (ii) laundry cost and (iii) environmental impact.
	tabling member constituency	South West Bedfordshire
	tabling member printed	Andrew Selous
	uin	22265
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Government is working with NHS England and partner organisations across the health system to develop a standardised methodology, to assess the full value of medical technologies. This initiative underlines our commitment in the Medtech Strategy, published in February 2023, ensuring the right product, in the right place, at the right price. The methodology will seek to look beyond upfront cost to consider patient outcomes, whole system costs, supply resilience, and the environmental impact when procurement decisions are being made.</p><p> </p><p>The methodology will provide a consistent approach to assessing value, and will be implemented at both the national and local level. This approach aims to ensure that procurement decisions support both short-term efficiencies and long-term benefits, drawing out the value to patients and the healthcare system. The Government appreciates contributions from the industry and procurement communities, and will invite stakeholders to provide feedback on the initial proposal in due course.</p><p> </p><p>In terms of implementation, we will look to align and integrate this initiative with NHS England’s Central Commercial Function's ongoing work under their strategic framework, which aims to create commercial playbooks for standardising practices and processes across the National Health Service.</p><p> </p><p>Regarding the specific point raised around absorbent continence products, the Disposable Continence tender is due to be issued to the market later this year. To ensure that the NHS’s requirements are considered during the procurement process, NHS Supply Chain is undertaking significant engagement across the health and social care system. This includes customers in the acute and wider community setting, suppliers, trade associations, professional bodies, and end user reference groups, to understand their requirements from a commercial, value, sustainability, and supply resilience perspective.</p><p> </p><p>NHS Supply Chain is currently working with suppliers of disposable continence products to understand the value-based procurement and sustainability offerings on the purchase of continence products. NHS Supply Chain has identified a trust who are committed in supporting us in understanding this value in the form of a pilot study, and potential case study. More information can be provided once these studies have been finalised and confirmed.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 21932 21933 question first answered 22/04/2024 11:00:01 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	1453 label Biography information for Andrew Selous

1701733

	registered interest
	date	17/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Dementia: Northern Ireland
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether Northern Ireland will receive funding through the Dame Barbara Windsor Dementia mission; and what her planned timetable for delivery of the mission is.
	tabling member constituency	East Londonderry
	tabling member printed	Mr Gregory Campbell
	uin	22258
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>Spending and delivery plans for the Dame Barbara Windsor Dementia Mission are currently in development. The Dementia Mission Co-Chairs Hilary Evans and Professor Nadeem Sarwar have, and continue to, engage extensively across the sector to understand and develop the missions’ key aims, ensuring it addresses the challenges the sector faces and that patient voices are heard. This has informed the missions focus on three key pillars: biomarkers and experimental medicine; clinical trials infrastructure and innovation; and end-to-end implementation.</p><p>In March 2024, the Government hosted a roundtable and reception where charities, academics, investors, business leaders, and people with lived experience came together to further accelerate efforts to tackle this devastating illness, and to thank all those involved in supporting dementia research, including charities across the United Kingdom. This event made a series announcements, including: awarding a share of the £6 million of funding to 10 projects through Innovate UK’s Small Business Research Initiative (SBRI) dementia biomarker tools competition; the appointment of Scott Mitchell as the People’s Champion for the Dementia Mission; the appointment of Dr Ruth McKernan CBE as Chair of the Scientific Advisory Board for the Neurodegeneration Initiative, which will be a public-private partnership delivering the mission's objectives around biomarkers, boosting the number and speed of clinical trials in dementia and neurodegeneration, and working with regulatory bodies around the implementation of new treatments; and the appointment of the Medicines Discovery Catapult as the delivery partner for the establishment of the Neurodegeneration Initiative. The Dame Barbara Windsor Dementia Mission continues to develop its deliverables, and will announce further plans for their delivery in due course.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/04/2024 10:51:18 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	1409 label Biography information for Mr Gregory Campbell

1701762

	registered interest
	date	17/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Paediatrics: Waiting Lists
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many children have been waiting longer than (a) 18 and (b) 24 months for a community paediatric appointment as of 17 April 2024.
	tabling member constituency	Bristol South
	tabling member printed	Karin Smyth
	uin	22319
	answer	answer is ministerial correction date of answer // answer text <p>The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered // answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4444 label Biography information for Karin Smyth

1701763

	registered interest
	date	17/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Paediatrics: Staff
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many NHS staff have worked in community paediatric services on average in each of the last 10 years.
	tabling member constituency	Bristol South
	tabling member printed	Karin Smyth
	uin	22320
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Department does not hold the information requested.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/04/2024 14:15:57 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4444 label Biography information for Karin Smyth

1701764

	registered interest
	date	17/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Community Health Services: Nurses
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many nurses have worked in NHS community health services on average in each of the last 10 years.
	tabling member constituency	Bristol South
	tabling member printed	Karin Smyth
	uin	22321
	answer	answer is ministerial correction date of answer // answer text <p>The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered // answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4444 label Biography information for Karin Smyth

1701846

	registered interest
	date	17/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Breast Cancer: Ethnic Groups
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to improve breast cancer outcomes amongst Black women.
	tabling member constituency	Brent Central
	tabling member printed	Dawn Butler
	uin	22274
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>Reducing inequalities and improving breast cancer outcomes for ethnic minority women, including black women, is a priority for the Government. To support this work, NHS England has commissioned six new cancer clinical audits, which will provide timely evidence for cancer service providers of where patterns of care in England may vary, increase the consistency of access to treatments, and help stimulate improvements in cancer treatments and outcomes for patients, including metastatic breast cancer. The Royal College of Surgeons began work on this audit in October 2022, and the first outcomes are expected in September 2024.</p><p> </p><p>NHS England is also leading a programme of work to tackle healthcare inequalities centred around five clear priorities, which are set out in operational planning guidance for the health system. The Core20PLUS5 approach for adults has been rolled out as an NHS England framework to focus action on reducing inequalities on issues within the National Health Services’ direct influence, which are major contributors to inequalities in life expectancy through major conditions like cancer, cardiovascular disease, respiratory disease, and others, or Long-Term Plan priorities where stark inequalities are evident, such as maternity or severe mental illness.</p><p> </p><p>The key actions for systems as highlighted in NHS England’s planning guidance for 2024/25 is to continue to deliver against the five strategic priorities for tackling health inequalities. Additionally, by the end of June 2024, NHS England aims to publish joined-up action plans to address health inequalities, and implement the Core20PLUS5 approach.</p><p> </p><p>Improving earlier diagnosis of cancers, including breast cancer, is also a priority for the Government. The NHS has an ambition to diagnose 75% of cancers at stage 1 or 2 by 2028, which will help tens of thousands of people live for longer. Additionally, the new cancer standards developed and supported by cancer doctors and implemented in October 2023, will ensure patients are diagnosed faster, and that treatment starts earlier. In the 2023/24 Operational Planning Guidance, NHS England announced that it is providing over £390 million in cancer service development funding to Cancer Alliances in each of the next two years, to support the delivery of the strategy and the operational priorities for cancer, which includes increasing and prioritising diagnostic and treatment capacity.</p><p> </p><p>Whilst the Major Conditions Strategy does not seek to describe everything that is being done, or could be done, to meet the challenges of individual conditions in silo, it instead focuses on the changes likely to make the most difference across the six groups of major conditions, including cancer.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 22275 question first answered 22/04/2024 15:43:26 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	1489 label Biography information for Dawn Butler

1701848

	registered interest
	date	17/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Breast Cancer: Ethnic Groups
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to help ensure the Major Conditions Strategy improves breast cancer outcomes for ethnic minority women.
	tabling member constituency	Brent Central
	tabling member printed	Dawn Butler
	uin	22275
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>Reducing inequalities and improving breast cancer outcomes for ethnic minority women, including black women, is a priority for the Government. To support this work, NHS England has commissioned six new cancer clinical audits, which will provide timely evidence for cancer service providers of where patterns of care in England may vary, increase the consistency of access to treatments, and help stimulate improvements in cancer treatments and outcomes for patients, including metastatic breast cancer. The Royal College of Surgeons began work on this audit in October 2022, and the first outcomes are expected in September 2024.</p><p> </p><p>NHS England is also leading a programme of work to tackle healthcare inequalities centred around five clear priorities, which are set out in operational planning guidance for the health system. The Core20PLUS5 approach for adults has been rolled out as an NHS England framework to focus action on reducing inequalities on issues within the National Health Services’ direct influence, which are major contributors to inequalities in life expectancy through major conditions like cancer, cardiovascular disease, respiratory disease, and others, or Long-Term Plan priorities where stark inequalities are evident, such as maternity or severe mental illness.</p><p> </p><p>The key actions for systems as highlighted in NHS England’s planning guidance for 2024/25 is to continue to deliver against the five strategic priorities for tackling health inequalities. Additionally, by the end of June 2024, NHS England aims to publish joined-up action plans to address health inequalities, and implement the Core20PLUS5 approach.</p><p> </p><p>Improving earlier diagnosis of cancers, including breast cancer, is also a priority for the Government. The NHS has an ambition to diagnose 75% of cancers at stage 1 or 2 by 2028, which will help tens of thousands of people live for longer. Additionally, the new cancer standards developed and supported by cancer doctors and implemented in October 2023, will ensure patients are diagnosed faster, and that treatment starts earlier. In the 2023/24 Operational Planning Guidance, NHS England announced that it is providing over £390 million in cancer service development funding to Cancer Alliances in each of the next two years, to support the delivery of the strategy and the operational priorities for cancer, which includes increasing and prioritising diagnostic and treatment capacity.</p><p> </p><p>Whilst the Major Conditions Strategy does not seek to describe everything that is being done, or could be done, to meet the challenges of individual conditions in silo, it instead focuses on the changes likely to make the most difference across the six groups of major conditions, including cancer.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 22274 question first answered 22/04/2024 15:43:26 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	1489 label Biography information for Dawn Butler

1701863

	registered interest
	date	17/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what funding has her Department allocated to provide recovery spaces for families of cancer treatment patients.
	tabling member constituency	Wirral South
	tabling member printed	Alison McGovern
	uin	22297
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Government is working jointly with NHS England on implementing the delivery plan for tackling the COVID-19 backlogs in elective care, and plans to spend more than £8 billion from 2022/23 to 2024/25 to help drive up and protect elective activity, including cancer treatment, which encompasses recovery spaces. Additionally, and as outlined in the 2024/25 NHS England Planning Guidance, NHS England are providing over £266 million in cancer service development funding to Cancer Alliances, to support delivery of the operational priorities for cancer.</p><p>The Department and NHS England meet regularly to discuss a wide range of issues regarding cancer. The Department's ministers and officials also frequently meet with key stakeholders within the cancer community, including discussions on support for patients and their families. As stated in the NHS Long Term Plan for Cancer, where appropriate, every person diagnosed with cancer will have access to personalised care, including needs assessment, a care plan and health and wellbeing information, and support. NHS England provides personalised cancer care and support plans, to support both patients and their families at all stages of their cancer journey. This is being delivered in line with the NHS Comprehensive Model for Personalised Care, empowering people to manage their care and the impact of their cancer, and maximise the potential of digital and community-based support. NHS England estimates that approximately 80% of cancer multidisciplinary teams are now offering Personalised Care and Support Planning, ensuring physical, practical, emotional, and social needs are identified and addressed at all stages of the cancer pathway. Additionally, Personalised Stratified Follow Up pathways, which adapt care to the needs of individual patients after cancer treatment, are being rolled out by cancer multi-disciplinary teams, and are required for at least eight cancer types by 2023/24.</p><p>General practice surgeries also conduct cancer care reviews at regular intervals after cancer diagnosis, to offer support with any needs patients may have. This includes providing access to other specialist-led services who work alongside patients’ medical teams, to support patients and their families, such as counsellors, rehabilitation specialists, or social prescribers, who can connect you to community groups or services for more support. This is part of NHS England’s drive to universal personalised care that will see at least 2.5 million people benefiting from personalised care by 2023/24.</p><p>NHS England and the integrated care boards are responsible for commissioning and ensuring the healthcare needs of local communities in England are met, including for cancer patients. NHS England provide access to a personal health budget, which is an amount of NHS money that is allocated to support the health and wellbeing needs of a patient if eligible. More information is available at the following link:</p><p><a href="https://www.nhs.uk/nhs-services/help-with-health-costs/what-is-a-personal-health-budget/" target="_blank">https://www.nhs.uk/nhs-services/help-with-health-costs/what-is-a-personal-health-budget/</a></p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 22298 question first answered 22/04/2024 11:02:18 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4083 label Biography information for Alison McGovern

1701890

	registered interest
	date	17/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions her Department has had with cancer treatment support groups on the use of direct funds to support patients and their families.
	tabling member constituency	Wirral South
	tabling member printed	Alison McGovern
	uin	22298
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Government is working jointly with NHS England on implementing the delivery plan for tackling the COVID-19 backlogs in elective care, and plans to spend more than £8 billion from 2022/23 to 2024/25 to help drive up and protect elective activity, including cancer treatment, which encompasses recovery spaces. Additionally, and as outlined in the 2024/25 NHS England Planning Guidance, NHS England are providing over £266 million in cancer service development funding to Cancer Alliances, to support delivery of the operational priorities for cancer.</p><p>The Department and NHS England meet regularly to discuss a wide range of issues regarding cancer. The Department's ministers and officials also frequently meet with key stakeholders within the cancer community, including discussions on support for patients and their families. As stated in the NHS Long Term Plan for Cancer, where appropriate, every person diagnosed with cancer will have access to personalised care, including needs assessment, a care plan and health and wellbeing information, and support. NHS England provides personalised cancer care and support plans, to support both patients and their families at all stages of their cancer journey. This is being delivered in line with the NHS Comprehensive Model for Personalised Care, empowering people to manage their care and the impact of their cancer, and maximise the potential of digital and community-based support. NHS England estimates that approximately 80% of cancer multidisciplinary teams are now offering Personalised Care and Support Planning, ensuring physical, practical, emotional, and social needs are identified and addressed at all stages of the cancer pathway. Additionally, Personalised Stratified Follow Up pathways, which adapt care to the needs of individual patients after cancer treatment, are being rolled out by cancer multi-disciplinary teams, and are required for at least eight cancer types by 2023/24.</p><p>General practice surgeries also conduct cancer care reviews at regular intervals after cancer diagnosis, to offer support with any needs patients may have. This includes providing access to other specialist-led services who work alongside patients’ medical teams, to support patients and their families, such as counsellors, rehabilitation specialists, or social prescribers, who can connect you to community groups or services for more support. This is part of NHS England’s drive to universal personalised care that will see at least 2.5 million people benefiting from personalised care by 2023/24.</p><p>NHS England and the integrated care boards are responsible for commissioning and ensuring the healthcare needs of local communities in England are met, including for cancer patients. NHS England provide access to a personal health budget, which is an amount of NHS money that is allocated to support the health and wellbeing needs of a patient if eligible. More information is available at the following link:</p><p><a href="https://www.nhs.uk/nhs-services/help-with-health-costs/what-is-a-personal-health-budget/" target="_blank">https://www.nhs.uk/nhs-services/help-with-health-costs/what-is-a-personal-health-budget/</a></p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 22297 question first answered 22/04/2024 11:02:18 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4083 label Biography information for Alison McGovern

1701903

	registered interest
	date	17/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Rare Diseases: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to support effective routes to market for precision medicines for (a) motor neurone disease and (b) other rare diseases in the UK.
	tabling member constituency	Northampton South
	tabling member printed	Andrew Lewer
	uin	22376
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>Should the Medicines and Healthcare products Regulatory Agency (MHRA) receive a marketing authorisation application (MAA) or applications, the MHRA will consider the drug with regards to quality, safety, and efficacy. The MHRA has procedures in place to consider drugs as part of an accelerated pathway. This is possible as part of national access collaboration, and international recognition. The MHRA would be able to consider motor neurone disease and other rare disease treatment products, under any of the procedures for the benefit of patients.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/04/2024 16:29:38 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4659 label Biography information for Andrew Lewer

1701915

	registered interest
	date	17/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Life Sciences: Artificial Intelligence
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what progress his Department has made on the £100 million AI Life Sciences Accelerator Mission.
	tabling member constituency	Hove
	tabling member printed	Peter Kyle
	uin	22347
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Prime Minister announced a new artificial intelligence (AI) in healthcare fund, backed by £100 million, at the AI Safety Summit. The Department for Science, Innovation and Technology is responsible for this fund, and the Department of Health and Social Care is working closely with them to identify areas where rapid deployment of AI could create transformational breakthroughs in healthcare. We are particularly focused on innovations in Life Sciences, which could accelerate our fight against devastating conditions like cancer and chronic mental ill-health, aiming to diagnose these conditions earlier and improve treatments. The Department for Science, Innovation and Technology will provide an update on our progress later in Spring.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/04/2024 10:56:22 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4505 label Biography information for Peter Kyle

1701263

	registered interest
	date	16/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Semaglutide: Health Hazards
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to increase the public's awareness of the side effects that can arise from taking weight loss drugs such as Ozempic.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	21989
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) plays a pivotal role in ensuring the safety, efficacy, and quality of medicines and healthcare products available to patients in the United Kingdom. Patient safety remains the MHRA’s highest priority, and they take every opportunity to encourage reporting of any safety concerns to the Yellow Card scheme, which helps to improve the safe use of medicines and medical devices for everyone.</p><p>New medicines including, Mounjaro and Wegovy, are intensively monitored to ensure that any new safety concerns are identified promptly. The Commission on Human Medicines and the MHRA encourages the reporting of all suspected reactions to newer drugs and vaccines, which are denoted by an inverted Black Triangle symbol. This symbol appears next to the name of a relevant product in drug safety updates, the British National Formulary and the Nurse Prescribers’ Formulary, the monthly index of medical specialities, the electronic medicines compendium, and advertising material. Patient information leaflets accompanying licensed medicines in the UK must include a description of the adverse reactions which may occur in normal use of the medicinal product, as well as information on how to report them. All adverse reactions must be reflected in the leaflet, in language that the patient will understand.</p><p>The MHRA has received a small number of reports of falsified and unlicenced medicines being sold illegally online as a treatment for weight loss. The agency has issued public health messaging warning of the dangers of buying such medicines from illegal trading sources online.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/04/2024 11:07:07 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4131 label Biography information for Jim Shannon

1701288

	registered interest
	date	16/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Lung Cancer: Public Health
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether she has made a recent assessment of the effectiveness of the help us, help you campaign.
	tabling member constituency	East Londonderry
	tabling member printed	Mr Gregory Campbell
	uin	21912
	answer	answer is ministerial correction date of answer 19/04/2024 answer text <p>No recent assessment has been made. In 2020 NHS England launched the Help Us, Help You (HUHY) campaigns, a major public information campaign to persuade the public to seek urgent care and treatment when they needed it. The HUHY campaign strategy is designed to address the underlying barriers to cancer diagnosis, including multifaceted fears and a lack of body vigilance, along with the lack of knowledge of cancer symptoms, to encourage people to present earlier.</p><p>On 8 January 2024, NHS England relaunched the HUHY campaign for cancer, designed to increase earlier diagnosis of cancer by reducing barriers to seeking earlier help, as well as increasing body vigilance and knowledge of key red flag symptoms. This campaign addresses barriers to people coming forward with suspected signs of cancer in general, and is not specific to screening or cervical cancer.</p><p>We are seeing continued high levels of urgent cancer referrals, which suggests the HUHY campaigns continue to be effective. Over 12,000 urgent referrals were seen for suspected cancer per working day in February 2024, compared to approximately 9,000 in January 2020.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 19/04/2024 07:32:51 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	1409 label Biography information for Mr Gregory Campbell

1701290

	registered interest
	date	16/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what estimate she has made of the number and proportion of NHS providers that have adopted two stage shared decision-making across all admitted pathways.
	tabling member constituency	Bristol South
	tabling member printed	Karin Smyth
	uin	22045
	answer	answer is ministerial correction date of answer 19/04/2024 answer text <p>In May 2023, NHS England published guidance setting out five core perioperative care requirements relating to the care of adult patients awaiting planned inpatient surgery. One of these requirements is that patients must be involved in shared decision making regarding admitted pathways. NHS England does not collect data on the number of National Health Service providers that have adopted two stage shared decision making across all admitted pathways. NHS England’s published guidance is available at the following link:</p><p><a href="https://www.england.nhs.uk/long-read/earlier-screening-risk-assessment-and-health-optimisation-in-perioperative-pathways/#2-five-core-requirements-for-providers" target="_blank">https://www.england.nhs.uk/long-read/earlier-screening-risk-assessment-and-health-optimisation-in-perioperative-pathways/#2-five-core-requirements-for-providers</a></p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 19/04/2024 09:58:11 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4444 label Biography information for Karin Smyth

1701292

	registered interest
	date	16/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Nurses: Training
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many training places for district nurses her Department plans to make available in September 2025.
	tabling member constituency	Bristol South
	tabling member printed	Karin Smyth
	uin	22047
	answer	answer is ministerial correction date of answer 19/04/2024 answer text <p>The NHS Long Term Workforce, published on 30 June 2023, sets out an ambition to increase the number of district nursing training places to 842 in 2025.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 19/04/2024 07:34:01 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4444 label Biography information for Karin Smyth

1701367

	registered interest
	date	16/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Incontinence: Products
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps she is taking with NHS England to (a) promote the adoption of the principles of value-based procurement in the purchase and dispensing of absorbent continence products and (b) help ensure that those principles continue to be adopted in the context of short-term savings being pursued by NHS organisations.
	tabling member constituency	South West Bedfordshire
	tabling member printed	Andrew Selous
	uin	21932
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Government is working with NHS England and partner organisations across the health system to develop a standardised methodology, to assess the full value of medical technologies. This initiative underlines our commitment in the Medtech Strategy, published in February 2023, ensuring the right product, in the right place, at the right price. The methodology will seek to look beyond upfront cost to consider patient outcomes, whole system costs, supply resilience, and the environmental impact when procurement decisions are being made.</p><p> </p><p>The methodology will provide a consistent approach to assessing value, and will be implemented at both the national and local level. This approach aims to ensure that procurement decisions support both short-term efficiencies and long-term benefits, drawing out the value to patients and the healthcare system. The Government appreciates contributions from the industry and procurement communities, and will invite stakeholders to provide feedback on the initial proposal in due course.</p><p> </p><p>In terms of implementation, we will look to align and integrate this initiative with NHS England’s Central Commercial Function's ongoing work under their strategic framework, which aims to create commercial playbooks for standardising practices and processes across the National Health Service.</p><p> </p><p>Regarding the specific point raised around absorbent continence products, the Disposable Continence tender is due to be issued to the market later this year. To ensure that the NHS’s requirements are considered during the procurement process, NHS Supply Chain is undertaking significant engagement across the health and social care system. This includes customers in the acute and wider community setting, suppliers, trade associations, professional bodies, and end user reference groups, to understand their requirements from a commercial, value, sustainability, and supply resilience perspective.</p><p> </p><p>NHS Supply Chain is currently working with suppliers of disposable continence products to understand the value-based procurement and sustainability offerings on the purchase of continence products. NHS Supply Chain has identified a trust who are committed in supporting us in understanding this value in the form of a pilot study, and potential case study. More information can be provided once these studies have been finalised and confirmed.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 21933 22265 question first answered 22/04/2024 11:00:01 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	1453 label Biography information for Andrew Selous

1701368

	registered interest
	date	16/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Incontinence: Products
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether she is taking steps to ensure that NHS organisations take into account (a) patient experience and outcomes, (b) whole system costs, (c) laundry costs and (d) the environmental impact when purchasing absorbent continence products.
	tabling member constituency	South West Bedfordshire
	tabling member printed	Andrew Selous
	uin	21933
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Government is working with NHS England and partner organisations across the health system to develop a standardised methodology, to assess the full value of medical technologies. This initiative underlines our commitment in the Medtech Strategy, published in February 2023, ensuring the right product, in the right place, at the right price. The methodology will seek to look beyond upfront cost to consider patient outcomes, whole system costs, supply resilience, and the environmental impact when procurement decisions are being made.</p><p> </p><p>The methodology will provide a consistent approach to assessing value, and will be implemented at both the national and local level. This approach aims to ensure that procurement decisions support both short-term efficiencies and long-term benefits, drawing out the value to patients and the healthcare system. The Government appreciates contributions from the industry and procurement communities, and will invite stakeholders to provide feedback on the initial proposal in due course.</p><p> </p><p>In terms of implementation, we will look to align and integrate this initiative with NHS England’s Central Commercial Function's ongoing work under their strategic framework, which aims to create commercial playbooks for standardising practices and processes across the National Health Service.</p><p> </p><p>Regarding the specific point raised around absorbent continence products, the Disposable Continence tender is due to be issued to the market later this year. To ensure that the NHS’s requirements are considered during the procurement process, NHS Supply Chain is undertaking significant engagement across the health and social care system. This includes customers in the acute and wider community setting, suppliers, trade associations, professional bodies, and end user reference groups, to understand their requirements from a commercial, value, sustainability, and supply resilience perspective.</p><p> </p><p>NHS Supply Chain is currently working with suppliers of disposable continence products to understand the value-based procurement and sustainability offerings on the purchase of continence products. NHS Supply Chain has identified a trust who are committed in supporting us in understanding this value in the form of a pilot study, and potential case study. More information can be provided once these studies have been finalised and confirmed.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 21932 22265 question first answered 22/04/2024 11:00:01 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	1453 label Biography information for Andrew Selous

1701431

	registered interest
	date	16/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Patients: Safety
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment she has made of the effectiveness of NHS speak up guardians in (a) primary and (b) secondary care settings.
	tabling member constituency	York Central
	tabling member printed	Rachael Maskell
	uin	22064
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>Freedom to Speak Up Guardians are a valued channel through which concerns can be raised, and have handled over 100,000 cases since the National Guardian’s Office first started collecting data in 2017. This represents over 100,000 opportunities for learning and improvement. In 2022/23 alone over 25,000 cases were raised with Freedom to Speak Up Guardians and over four-fifths, or 82.2% of those who gave feedback to their Freedom to Speak Up Guardian, said they would speak up again.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/04/2024 10:55:12 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4471 label Biography information for Rachael Maskell

1701449

	registered interest
	date	16/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Bootham Park Hospital
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what progress NHS Property Services Ltd has made on the disposal of Bootham Park Hospital.
	tabling member constituency	York Central
	tabling member printed	Rachael Maskell
	uin	22068
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The sales process for the former Bootham Park Hospital is progressing, and is subject to final legal agreements with City of York Council. This sale would provide a range of public benefits, which include ensuring public access through the site, the provision of a formal cycle path, a publicly accessible park, and additional sports facilities which will be available for use by local schools.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/04/2024 16:28:22 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4471 label Biography information for Rachael Maskell

1701459

	registered interest
	date	16/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Semaglutide: Procurement
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps she is taking with pharmaceutical companies to increase the supply of semaglutide.
	tabling member constituency	West Lancashire
	tabling member printed	Ashley Dalton
	uin	22201
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Department has worked intensively with industry to seek commitments from them to address issues with the supply of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide, to expedite deliveries and boost supplies. As a result, the overall supply position in the United Kingdom has improved. Guidance for healthcare professionals now allows for the initiation of new patients on Rybelsus tablets, an oral semaglutide, and provides advice on what to prescribe patients who are unable to obtain their existing GLP-1 RA treatment whilst there continue to be disruptions to the supply of some products, including semaglutide. These disruptions are affecting many countries around the world, and aren’t specific to the UK.</p><p>We continue to work with international partners, given the global nature of medical supply chains, collaborating to share best practice and manage and respond to common threats to supply, including on semaglutide and other GLP-1 RAs licensed for treating patients with type 2 diabetes.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 22202 22203 question first answered 22/04/2024 09:40:27 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4981 label Biography information for Ashley Dalton

1701460

	registered interest
	date	16/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Semaglutide: Diabetes
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of the guidance submitted to medical professions on the prescription of semaglutide on the availability of that drug for people suffering from type 2 diabetes.
	tabling member constituency	West Lancashire
	tabling member printed	Ashley Dalton
	uin	22202
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Department has worked intensively with industry to seek commitments from them to address issues with the supply of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide, to expedite deliveries and boost supplies. As a result, the overall supply position in the United Kingdom has improved. Guidance for healthcare professionals now allows for the initiation of new patients on Rybelsus tablets, an oral semaglutide, and provides advice on what to prescribe patients who are unable to obtain their existing GLP-1 RA treatment whilst there continue to be disruptions to the supply of some products, including semaglutide. These disruptions are affecting many countries around the world, and aren’t specific to the UK.</p><p>We continue to work with international partners, given the global nature of medical supply chains, collaborating to share best practice and manage and respond to common threats to supply, including on semaglutide and other GLP-1 RAs licensed for treating patients with type 2 diabetes.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 22201 22203 question first answered 22/04/2024 09:40:27 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4981 label Biography information for Ashley Dalton

1701461

	registered interest
	date	16/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether she is working with her international counterparts to tackle supply issues relating to (a) semaglutide and (b) other glucagon-like peptide-1 receptor agonists licensed for treating patients with type 2 diabetes.
	tabling member constituency	West Lancashire
	tabling member printed	Ashley Dalton
	uin	22203
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Department has worked intensively with industry to seek commitments from them to address issues with the supply of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide, to expedite deliveries and boost supplies. As a result, the overall supply position in the United Kingdom has improved. Guidance for healthcare professionals now allows for the initiation of new patients on Rybelsus tablets, an oral semaglutide, and provides advice on what to prescribe patients who are unable to obtain their existing GLP-1 RA treatment whilst there continue to be disruptions to the supply of some products, including semaglutide. These disruptions are affecting many countries around the world, and aren’t specific to the UK.</p><p>We continue to work with international partners, given the global nature of medical supply chains, collaborating to share best practice and manage and respond to common threats to supply, including on semaglutide and other GLP-1 RAs licensed for treating patients with type 2 diabetes.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 22201 22202 question first answered 22/04/2024 09:40:27 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4981 label Biography information for Ashley Dalton

1701471

	registered interest
	date	16/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Breast Cancer: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to improve access to breast screening for people with physical disabilities that prevent them from holding the required position for sufficient time to complete the screening.
	tabling member constituency	North Shropshire
	tabling member printed	Helen Morgan
	uin	22193
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>NHS England is committed to improving the accessibility of the screening programmes it commissions under the Public Health Services (S7a) agreement, particularly for under-served groups in society. Contractually, providers of National Health Service screening services are required to make reasonable adjustments to ensure that their services are accessible for people with disabilities. For example, the NHS breast screening service offers longer appointments at accessible sites to support women with physical disabilities.</p><p>Services make reasonable adjustments within the constraints of mammography equipment, to ensure that people with disabilities are offered the opportunity to have screening. However, there may be situations where this is not possible. Providers will deal with these on a case by case basis, and offer an alternative approach as necessary. For example, for women who are unable to have a mammogram, they may be offered a referral to a symptomatic breast clinic for a physical check.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/04/2024 10:53:55 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4934 label Biography information for Helen Morgan

1701496

	registered interest
	date	16/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Mental Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will bring forward legislative proposals to protect the titles for all (a) psychologists, (b) psychotherapists, (c) counsellors and (d) other psychological therapy providers.
	tabling member constituency	City of Durham
	tabling member printed	Mary Kelly Foy
	uin	22164
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>All professional healthcare regulators have protected titles, relating to the professions they regulate. There are currently 64 protected titles across 10 professional health and care regulators, including nine protected titles relating to the practitioner psychologist profession, regulated by the Health and Care Professions Council.</p><p>Titles can only be protected for statutorily regulated professions. There are no plans to statutorily regulate psychologist, psychotherapist, counsellor, or other psychological therapy provider roles.</p><p>The Government keeps the professions subject to statutory regulation under review and in 2022 published the consultation, Healthcare regulation: deciding when statutory regulation is appropriate, seeking views on the criteria used to decide when regulation is necessary, and whether there are any unregulated professions that should be brought into statutory regulation. The Government will publish its response to the consultation in due course.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/04/2024 15:44:54 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4753 label Biography information for Mary Kelly Foy

1701580

	registered interest
	date	16/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Barts Health NHS Trust
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions her Department has had with NHS England and Barts Health NHS Trust on the ongoing dispute.
	tabling member constituency	Warrington North
	tabling member printed	Charlotte Nichols
	uin	22171
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>Department officials have held discussions with NHS England regarding the strike action held at Barts Health NHS Trust. However, this is a local dispute that should be managed locally by the trust, so no direct discussions have been held with Barts Health NHS Trust on this matter.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/04/2024 15:41:36 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4799 label Biography information for Charlotte Nichols

1701585

	registered interest
	date	16/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS Trusts: Procurement
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to return NHS Trusts to pre-pandemic procurement practices.
	tabling member constituency	Tamworth
	tabling member printed	Sarah Edwards
	uin	22209
	answer	answer is ministerial correction date of answer 23/04/2024 answer text <p>Guidance on how contracting authorities, including National Health Service trusts, should respond to the COVID-19 pandemic was published in March 2020 and February 2021, reminding them of the options available when undertaking procurements in an emergency. These two guidance documents are available, respectively, at the following links:</p><p><a href="https://www.gov.uk/government/publications/procurement-policy-note-0120-responding-to-covid-19" target="_blank">https://www.gov.uk/government/publications/procurement-policy-note-0120-responding-to-covid-19</a></p><p><a href="https://www.gov.uk/government/publications/procurement-policy-note-0121-procurement-in-an-emergency" target="_blank">https://www.gov.uk/government/publications/procurement-policy-note-0121-procurement-in-an-emergency</a></p><p>Authorities are allowed to procure goods, services, and works with extreme urgency in exceptional circumstances, using regulation 32(2)(c) under the Public Contract Regulations 2015. These include a direct award under which authorities may enter into contracts without competing or advertising the requirement.</p><p>Contracting authorities assess the market conditions for procuring supplies related to any procurement, in accordance with procurement guidance and regulations. Where any procurement meets the tests for the use of Regulation 32(2)(c) for the direct awarding of a contract, then that approach can be used. However, where it doesn’t, other approaches will be considered.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 23/04/2024 08:14:50 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	5001 label Biography information for Sarah Edwards

1700831

	registered interest
	date	15/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Surgery: Suffolk
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to reduce waiting times for elective surgery for people in Suffolk Coastal constituency.
	tabling member constituency	Suffolk Coastal
	tabling member printed	Dr Thérèse Coffey
	uin	21635
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Department plans to spend more than £8 billion from 2022/23 to 2024/25 to increase National Health Service elective activity and productivity above pre-pandemic levels, while expanding capacity through creating a new network of community diagnostic centres and maximising all available independent sector capacity.</p><p>NHS England provides robust support and challenge to the trusts which have the highest number of patients waiting the longest for elective treatment, with each receiving bespoke regional or national intervention where it is required.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/04/2024 09:49:33 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4098 label Biography information for Dr Thérèse Coffey

1701015

	registered interest
	date	15/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Department of Health and Social Care: Marketing
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what proportion of her Department’s (a) advertising and (b) marketing expenditure was on (i) local newspapers in print and online, (ii) national newspapers in print and online, (iii) social media, (iv) search engines, (v) broadcast and on-demand television and (vi) other channels in the most recent year for which data is available.
	tabling member constituency	Barnsley East
	tabling member printed	Stephanie Peacock
	uin	21750
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The below table shows the Department’s total media expenditure, across advertising and marketing and as a proportion by media type, for the financial year 2023/24:<br></p><table><tbody><tr><td><p>Type of media</p></td><td><p>Percentage of departmental media expenditure</p></td></tr><tr><td><p>Local newspapers in print and online</p></td><td><p>10.3%</p></td></tr><tr><td><p>National newspapers in print and online</p></td><td><p>10.4%</p></td></tr><tr><td><p>Social media</p></td><td><p>7.5%</p></td></tr><tr><td><p>Search engines</p></td><td><p>4.7%</p></td></tr><tr><td><p>Broadcast and on-demand television</p></td><td><p>6.7%</p></td></tr><tr><td><p>Other channels, including radio, audio, out-of-home advertising, display, programmatic, and fees</p></td><td><p>60.4%</p></td></tr></tbody></table> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/04/2024 14:21:01 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4607 label Biography information for Stephanie Peacock

1701024

	registered interest
	date	15/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Incontinence: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will make it her policy to make an assessment of the potential impact of any proposed amendments to Part IX of the Drug Tariff on (a) patients with continence care needs, (b) continence care services, (c) the range of continence devices available to clinicians and patients and (d) new product development and innovation in medical devices in the continence sector.
	tabling member constituency	Stockport
	tabling member printed	Navendu Mishra
	uin	21863
	answer	answer is ministerial correction date of answer 18/04/2024 answer text <p>Part IX will remain a list of devices available to be prescribed in the community, via the FP10 prescription route. The Department believes that it is currently difficult to identify which devices are broadly comparable, and whether more expensive devices provide added value. The proposed amendments that were consulted on were intended to increase meaningful choice, not to decrease the choice for clinicians and patients. Comparison between products can increase awareness of different brands amongst prescribers, which can support small and medium sized businesses in entering the market.</p><p>The consultation response on the proposed amendments to Part IX is expected to be released in May 2024, which will outline the Government’s response. Any amendments that are taken forward will happen gradually, with review points and engagement with stakeholders, including industry, patient representatives, clinicians, and National Health Service organisations. We are aware that there are some very good devices in use, relied upon by clinicians and patients.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 18/04/2024 09:34:23 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4811 label Biography information for Navendu Mishra

1701026

	registered interest
	date	15/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Bowel Cancer: Greater Manchester
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent assessment her Department has made of the adequacy of bowel cancer diagnosis services in (a) Stockport and (b) Greater Manchester.
	tabling member constituency	Stockport
	tabling member printed	Navendu Mishra
	uin	21865
	answer	answer is ministerial correction date of answer 18/04/2024 answer text <p>The Department continues to take steps to improve early diagnosis for all cancers, which encompasses bowel cancer, and in all areas, including Stockport and Greater Manchester. The Department is working jointly with NHS England on implementing the Delivery Plan for Tackling the COVID-19 Backlog of Elective Care, which includes plans to spend more than £8 billion from 2022/23 to 2024/25 to help drive up and protect elective activity, including cancer diagnosis and treatment.</p><p>NHS England is working to meet the Faster Diagnosis Standard (FDS), which sets a target of 28 days from urgent referral by a general practitioner or screening programme to patients being told that they have cancer, or that cancer is ruled out. To achieve this target, NHS England has: streamlined bowel cancer pathways by implementing faecal immunochemical testing (FIT) triage for patients in primary and secondary care settings; implemented non-symptom specific pathways for patients; and opened community diagnostic centres across England, prioritising this capacity for cancer services. The latest published data from February 2024 shows FDS performance was 78.1% nationally. More specifically to bowel cancer, the latest published data shows that at a national level, the number of people diagnosed with bowel cancer has risen to 41,596 in 2021, compared to 37,702 diagnosed in 2019. Since the FIT kit was introduced into the bowel cancer screening programme in April 2019, national uptake has increased from 59.2% to 67.8%. the latest data for the North-West region shows that 64.3% of 60 to 74-year-olds completed their bowel screening in the first quarter of 2023/24.</p><p>In 2023 the NHS England’s Help Us Help You campaign urged people to take up the offer of bowel screening when invited, and the screening offer for the bowel screening programme is being gradually extended from age 60 down to 50 years old by 2025, ensuring more people are screened and potentially diagnosed with bowel cancer at the earliest stage.   NHS England is also now offering routine preventative bowel cancer screening to people with Lynch syndrome, with 94% of people on average receiving the test between 2021 and 2023, up from 47% in 2019.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 18/04/2024 09:37:22 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4811 label Biography information for Navendu Mishra

1701062

	registered interest
	date	15/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs: Wholesale Trade
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment she has made of the implications for her policies of the prices available to (a) large companies and (b) independent pharmacies for the purchase of pharmaceuticals from wholesalers.
	tabling member constituency	York Central
	tabling member printed	Rachael Maskell
	uin	21716
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>Through the medicine margin survey, the Department assesses whether the reimbursement arrangements pay pharmacy contractors as agreed, as part of the community pharmacy contractual framework. The medicine margin survey considers what a sample of independent pharmacies paid, by looking at their invoices compared to the amount reimbursed by the National Health Service. As large companies are considered to have greater buying power, they are not sampled in the medicine margin survey.</p><p>Furthermore, where pharmacies cannot purchase products at or below the Drug Tariff NHS reimbursement price, Community Pharmacy England can request that the Department reassesses the reimbursement price. If a new reimbursement price is issued, it is known as a concessionary price.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/04/2024 11:04:47 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4471 label Biography information for Rachael Maskell

1701064

	registered interest
	date	15/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pharmacy: Finance
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential merits of a rebate scheme for the cost of pharmaceuticals for community pharmacies.
	tabling member constituency	York Central
	tabling member printed	Rachael Maskell
	uin	21717
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>Community pharmacies are responsible for purchasing the medicines and other products that they supply as part of National Health Service pharmaceutical services. The purchase price, including rebates schemes available to them, is a commercial decision for the pharmaceutical wholesalers and manufacturers who sell to them.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/04/2024 11:03:41 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4471 label Biography information for Rachael Maskell

1699968

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pharmacy: Finance
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of medication costs on community pharmacies.
	tabling member constituency	Gosport
	tabling member printed	Dame Caroline Dinenage
	uin	20988
	answer	answer is ministerial correction date of answer 19/04/2024 answer text <p>Through the medicine margin survey, the Department assesses whether the reimbursement arrangements pay pharmacy contractors as agreed as part of the community pharmacy contractual framework (CPCF). The medicine margin survey considers what pharmacies paid for medicines by looking at their invoices compared to the amount reimbursed by the National Health Service. Where the survey finds that they have been underpaid, we increase the pharmacy contractors’ payments, and where they have been overpaid, we decrease payments.</p><p>Furthermore, where pharmacies cannot purchase products at or below the Drug Tariff NHS reimbursement price, Community Pharmacy England can request that the Department reassesses the reimbursement price. If a new reimbursement price is issued, this is known as a concessionary price.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20979 question first answered 19/04/2024 09:54:36 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4008 label Biography information for Dame Caroline Dinenage

1699971

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medical Equipment
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether she plans to develop a Priority Review programme for medical devices.
	tabling member constituency	Gosport
	tabling member printed	Dame Caroline Dinenage
	uin	20991
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Priority Review programme is not currently planned, but the Government is taking other significant steps for medical device regulatory reform, as part of a broader Medical Technology Strategy. Further information on the Medical Technology Strategy is available at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy" target="_blank">https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy</a></p><p> </p><p>The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating medical devices, and designates United Kingdom Approved Bodies to conduct conformity assessments against the relevant regulatory requirements. The MHRA works closely with Approved Bodies to ensure their timely assessment.</p><p> </p><p>Following a consultation on the future regulation of medical devices in 2021, the MHRA is leading a programme of work to introduce updated regulations for medical devices that prioritise patient safety, improve patient access to innovative medical devices, and ensure the UK remains an attractive market for medical technology innovators. In January of this year, the MHRA published a MedTech Regulatory roadmap that sets out the main activities in implementing the future regulations throughout 2024 and 2025. An international recognition framework for medical devices will form part of the future regulatory framework, which will provide an alternative route to the UK’s market, by leveraging approvals from comparable international regulators. The MHRA aims to publish an outline of the International Recognition Framework for medical devices later this spring, aligned to the Life Sciences Council, subject to necessary approvals.</p><p>In addition, the MHRA is leading the reform of the medical devices regulatory landscape and includes a new pathway to accelerate access to safe, innovative medical devices to help meet the unmet needs of patients. The Innovative Devices Access Pathway aims to bring new medical technologies and solutions to the National Health Service, to support the medical needs that are not currently being met. There are eight innovative medical technologies included in the pilot phase.</p><p>We are working alongside others to further the Life Sciences Vision, particularly improving regulation and regulatory processes around medical devices, and supporting broader ambitions in the vision aligned to the conditions set out in the Major Conditions Strategy. As we work to update the medical devices regulatory landscape, the MHRA is taking the Major Conditions Strategy into consideration, including the six groups of major health conditions.</p><p>The National Institute for Health and Care Excellence (NICE) is not a regulator but makes recommendations for the NHS on whether selected medical devices should be routinely adopted by the NHS, based on an assessment of their costs and benefits. Medical devices are prioritised for the NICE’s evaluation, in line with NICE’s published topic selection manual.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20992 20993 question first answered 22/04/2024 11:22:39 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4008 label Biography information for Dame Caroline Dinenage

1699972

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medical Equipment: Reviews
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the Answer of 23 June 2023 to Question 189729 on Medicines and Healthcare products Regulatory Agency, whether she plans to initiate a priority review for medical devices.
	tabling member constituency	Gosport
	tabling member printed	Dame Caroline Dinenage
	uin	20992
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Priority Review programme is not currently planned, but the Government is taking other significant steps for medical device regulatory reform, as part of a broader Medical Technology Strategy. Further information on the Medical Technology Strategy is available at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy" target="_blank">https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy</a></p><p> </p><p>The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating medical devices, and designates United Kingdom Approved Bodies to conduct conformity assessments against the relevant regulatory requirements. The MHRA works closely with Approved Bodies to ensure their timely assessment.</p><p> </p><p>Following a consultation on the future regulation of medical devices in 2021, the MHRA is leading a programme of work to introduce updated regulations for medical devices that prioritise patient safety, improve patient access to innovative medical devices, and ensure the UK remains an attractive market for medical technology innovators. In January of this year, the MHRA published a MedTech Regulatory roadmap that sets out the main activities in implementing the future regulations throughout 2024 and 2025. An international recognition framework for medical devices will form part of the future regulatory framework, which will provide an alternative route to the UK’s market, by leveraging approvals from comparable international regulators. The MHRA aims to publish an outline of the International Recognition Framework for medical devices later this spring, aligned to the Life Sciences Council, subject to necessary approvals.</p><p>In addition, the MHRA is leading the reform of the medical devices regulatory landscape and includes a new pathway to accelerate access to safe, innovative medical devices to help meet the unmet needs of patients. The Innovative Devices Access Pathway aims to bring new medical technologies and solutions to the National Health Service, to support the medical needs that are not currently being met. There are eight innovative medical technologies included in the pilot phase.</p><p>We are working alongside others to further the Life Sciences Vision, particularly improving regulation and regulatory processes around medical devices, and supporting broader ambitions in the vision aligned to the conditions set out in the Major Conditions Strategy. As we work to update the medical devices regulatory landscape, the MHRA is taking the Major Conditions Strategy into consideration, including the six groups of major health conditions.</p><p>The National Institute for Health and Care Excellence (NICE) is not a regulator but makes recommendations for the NHS on whether selected medical devices should be routinely adopted by the NHS, based on an assessment of their costs and benefits. Medical devices are prioritised for the NICE’s evaluation, in line with NICE’s published topic selection manual.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20991 20993 question first answered 22/04/2024 11:22:39 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4008 label Biography information for Dame Caroline Dinenage

1699973

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medical Equipment
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether (a) the Medicines and Healthcare products Regulatory Agency and (b) NICE will prioritise the regulatory timelines for medical devices that (i) respond to conditions outlined in the Major Conditions Strategy and (ii) where there is unmet need.
	tabling member constituency	Gosport
	tabling member printed	Dame Caroline Dinenage
	uin	20993
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Priority Review programme is not currently planned, but the Government is taking other significant steps for medical device regulatory reform, as part of a broader Medical Technology Strategy. Further information on the Medical Technology Strategy is available at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy" target="_blank">https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy</a></p><p> </p><p>The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating medical devices, and designates United Kingdom Approved Bodies to conduct conformity assessments against the relevant regulatory requirements. The MHRA works closely with Approved Bodies to ensure their timely assessment.</p><p> </p><p>Following a consultation on the future regulation of medical devices in 2021, the MHRA is leading a programme of work to introduce updated regulations for medical devices that prioritise patient safety, improve patient access to innovative medical devices, and ensure the UK remains an attractive market for medical technology innovators. In January of this year, the MHRA published a MedTech Regulatory roadmap that sets out the main activities in implementing the future regulations throughout 2024 and 2025. An international recognition framework for medical devices will form part of the future regulatory framework, which will provide an alternative route to the UK’s market, by leveraging approvals from comparable international regulators. The MHRA aims to publish an outline of the International Recognition Framework for medical devices later this spring, aligned to the Life Sciences Council, subject to necessary approvals.</p><p>In addition, the MHRA is leading the reform of the medical devices regulatory landscape and includes a new pathway to accelerate access to safe, innovative medical devices to help meet the unmet needs of patients. The Innovative Devices Access Pathway aims to bring new medical technologies and solutions to the National Health Service, to support the medical needs that are not currently being met. There are eight innovative medical technologies included in the pilot phase.</p><p>We are working alongside others to further the Life Sciences Vision, particularly improving regulation and regulatory processes around medical devices, and supporting broader ambitions in the vision aligned to the conditions set out in the Major Conditions Strategy. As we work to update the medical devices regulatory landscape, the MHRA is taking the Major Conditions Strategy into consideration, including the six groups of major health conditions.</p><p>The National Institute for Health and Care Excellence (NICE) is not a regulator but makes recommendations for the NHS on whether selected medical devices should be routinely adopted by the NHS, based on an assessment of their costs and benefits. Medical devices are prioritised for the NICE’s evaluation, in line with NICE’s published topic selection manual.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20991 20992 question first answered 22/04/2024 11:22:40 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4008 label Biography information for Dame Caroline Dinenage

1699978

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of discontinuing funding for T1DE pilot schemes on the health and well-being of patients living with type 1 diabetes with disordered eating.
	tabling member constituency	Knowsley
	tabling member printed	Sir George Howarth
	uin	20895
	answer	answer is ministerial correction date of answer 18/04/2024 answer text <p>NHS England has provided funding for eight integrated care boards (ICBs) across the country to support the development and establishment of Type 1 Diabetes with Disordered Eating (T1DE) services in every National Health Service region. Funding has been provided on a pump prime basis, and the responsibility for the longer-term sustainable provision of care for these patients sits with the relevant integrated care system.</p><p>A nationally commissioned evaluation has shown the positive impact that the provision of T1DE services can have for patients, including reductions in HbA1c, which is linked to reduced rates of diabetes complications, and reduced rates of emergency admissions.</p><p>It’s the role of the ICBs to consider the health needs of their populations, in making decisions about the care that is provided. It is expected that ICB leads consider these evaluation findings alongside the risk to patient health and wellbeing of the discontinuation of service provision, as well as other local contextual factors in making decisions about the future provision of T1DE services.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 18/04/2024 12:53:21 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	481 label Biography information for Sir George Howarth

1699979

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment her Department has made of the potential implications for its policies of the cost-benefit analysis of the T1DE pilot schemes carried out by NHS England.
	tabling member constituency	Knowsley
	tabling member printed	Sir George Howarth
	uin	20896
	answer	answer is ministerial correction date of answer 17/04/2024 answer text <p>Evaluation by the National Health Service of the initial Type 1 Diabetes with Disordered Eating service (T1DE) pilot sites, in London and Wessex, demonstrated a mean reduction in HbA1c of between 2.3% to 2.5%. Assuming that this level of reduction is maintained, the lifetime quality-adjusted life year gain of these services was estimated at 1.49, which would be cost effective up to a net lifetime cost of £29,800-£44,800.</p><p>In response to these initial evaluation findings, NHS England expanded the T1DE programme, supporting provision of new services in an additional five sites from September 2022, expanding coverage to more areas of the country. It is expected that these services will generate further evaluation data to consolidate these early findings, which can be used to inform national and local policy decisions.</p><p>NHS England is drawing on learning from existing T1DE services, other emerging evidence and the findings of the recent parliamentary inquiry, to ensure all areas of the country are supported to improve care for those identified as having T1DE. The emergence of these future plans are subject to future spending review settlements for the NHS and level of funding from the NHS England budget allocated to T1DE.</p><p>NHS England are also working closely with the first wave of pilot sites including London to ensure that the newer services can benefit from their learning and experience when considering local funding options in advance of March 2025, when the national funding for the five new sites will come to an end.<strong><br> </strong></p><p>NHS England is assisting integrated care boards to develop local funding arrangements through the provision of evaluation data, a national programme of support workshops, and an online platform to share learning and good practice.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20897 question first answered 17/04/2024 15:22:42 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	481 label Biography information for Sir George Howarth

1699980

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether she (a) has made and (b) plans to make an assessment of the potential merits of funding options to ensure the sustainability of T1DE services beyond the pilot phase.
	tabling member constituency	Knowsley
	tabling member printed	Sir George Howarth
	uin	20897
	answer	answer is ministerial correction date of answer 17/04/2024 answer text <p>Evaluation by the National Health Service of the initial Type 1 Diabetes with Disordered Eating service (T1DE) pilot sites, in London and Wessex, demonstrated a mean reduction in HbA1c of between 2.3% to 2.5%. Assuming that this level of reduction is maintained, the lifetime quality-adjusted life year gain of these services was estimated at 1.49, which would be cost effective up to a net lifetime cost of £29,800-£44,800.</p><p>In response to these initial evaluation findings, NHS England expanded the T1DE programme, supporting provision of new services in an additional five sites from September 2022, expanding coverage to more areas of the country. It is expected that these services will generate further evaluation data to consolidate these early findings, which can be used to inform national and local policy decisions.</p><p>NHS England is drawing on learning from existing T1DE services, other emerging evidence and the findings of the recent parliamentary inquiry, to ensure all areas of the country are supported to improve care for those identified as having T1DE. The emergence of these future plans are subject to future spending review settlements for the NHS and level of funding from the NHS England budget allocated to T1DE.</p><p>NHS England are also working closely with the first wave of pilot sites including London to ensure that the newer services can benefit from their learning and experience when considering local funding options in advance of March 2025, when the national funding for the five new sites will come to an end.<strong><br> </strong></p><p>NHS England is assisting integrated care boards to develop local funding arrangements through the provision of evaluation data, a national programme of support workshops, and an online platform to share learning and good practice.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20896 question first answered 17/04/2024 15:22:42 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	481 label Biography information for Sir George Howarth

1700007

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pharmacy: Finance
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment she has made of the adequacy of the medication reimbursement mechanism for community pharmacists.
	tabling member constituency	Easington
	tabling member printed	Grahame Morris
	uin	20979
	answer	answer is ministerial correction date of answer 19/04/2024 answer text <p>Through the medicine margin survey, the Department assesses whether the reimbursement arrangements pay pharmacy contractors as agreed as part of the community pharmacy contractual framework (CPCF). The medicine margin survey considers what pharmacies paid for medicines by looking at their invoices compared to the amount reimbursed by the National Health Service. Where the survey finds that they have been underpaid, we increase the pharmacy contractors’ payments, and where they have been overpaid, we decrease payments.</p><p>Furthermore, where pharmacies cannot purchase products at or below the Drug Tariff NHS reimbursement price, Community Pharmacy England can request that the Department reassesses the reimbursement price. If a new reimbursement price is issued, this is known as a concessionary price.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20988 question first answered 19/04/2024 09:54:35 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3973 label Biography information for Grahame Morris

1700034

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Trastuzumab Deruxtecan
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will make a comparative assessment of the adequacy of the reasons the (a) National Institute for Health and Care Excellence has been unable and (b) Scottish Medicines Consortium has been able to recommend Enhertu for use on the NHS.
	tabling member constituency	Brighton, Pavilion
	tabling member printed	Caroline Lucas
	uin	20959
	answer	answer is ministerial correction date of answer 16/04/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) makes authoritative, evidence-based recommendations for the National Health Service in England on whether new licensed medicines should be routinely funded by the NHS, based on an assessment of their costs and benefits. Decisions on the availability of medicines in Scotland are a matter for the devolved administration.</p><p>The NICE published guidance in 2021 and 2023 recommending Enhertu, also known as trastuzumab deruxtecan, for the treatment of NHS patients with HER2-positive breast cancer through the Cancer Drugs Fund, and it is now available to eligible NHS patients in England in line with the NICE’s recommendations.</p><p>The NICE is currently evaluating Enhertu for the treatment of metastatic HER2-low breast cancer, and has not yet published final guidance. Stakeholders have had an opportunity to appeal against the NICE’s draft recommendations, and the NICE will consider any appeals through the established process and publish final guidance in due course.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/04/2024 15:01:22 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3930 label Biography information for Caroline Lucas

1700037

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health Services: Consultants
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many and what proportion of NHS consultants carried out work in the private sector in the most recent financial year for which data is available.
	tabling member constituency	Knowsley
	tabling member printed	Sir George Howarth
	uin	20900
	answer	answer is ministerial correction date of answer 17/04/2024 answer text <p>The Department does not hold the information requested.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 17/04/2024 10:23:50 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	481 label Biography information for Sir George Howarth

1700039

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Disability Aids
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what data her Department holds on how many useable mobility aids and equipment are wasted in the NHS each year.
	tabling member constituency	Huddersfield
	tabling member printed	Mr Barry Sheerman
	uin	20866
	answer	answer is ministerial correction date of answer 17/04/2024 answer text <p>As set out in the Delivering a Net Zero National Health Service report, published in October 2020, the NHS is committed to reducing its environmental impact, including by increasing the reuse and recycling of medical equipment. This commitment is then applied locally, taking into account local priorities, through local Green Plans.</p><p>NHS England also collaborates with the NHS Supply Chain to increase availability of reusable products, and supports local NHS organisations through the publication of guidance and resources to help with implementing changes.</p><p>Furthermore, the Department published the inaugural Medical Technology Strategy in February 2023, which included a focus on improving resource efficiency. The Department’s Design for Life Programme works with industry, the health and care sector, and academic partners to develop medical technology systems that support reuse, remanufacture, and material recovery becoming the default. The Department recognises we will need to define future data requirements and align digital infrastructure to improve the gathering of core data, such as how products are eventually disposed. The Department’s intention is to publish a roadmap later this year, to articulate our relevant findings and plans moving forward.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20867 question first answered 17/04/2024 14:13:08 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	411 label Biography information for Mr Barry Sheerman

1700040

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Disability Aids: Waste Disposal
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what information her Department holds on where the NHS disposes of (a) crutches, (b) wheelchairs and (c) other mobility equipment.
	tabling member constituency	Huddersfield
	tabling member printed	Mr Barry Sheerman
	uin	20867
	answer	answer is ministerial correction date of answer 17/04/2024 answer text <p>As set out in the Delivering a Net Zero National Health Service report, published in October 2020, the NHS is committed to reducing its environmental impact, including by increasing the reuse and recycling of medical equipment. This commitment is then applied locally, taking into account local priorities, through local Green Plans.</p><p>NHS England also collaborates with the NHS Supply Chain to increase availability of reusable products, and supports local NHS organisations through the publication of guidance and resources to help with implementing changes.</p><p>Furthermore, the Department published the inaugural Medical Technology Strategy in February 2023, which included a focus on improving resource efficiency. The Department’s Design for Life Programme works with industry, the health and care sector, and academic partners to develop medical technology systems that support reuse, remanufacture, and material recovery becoming the default. The Department recognises we will need to define future data requirements and align digital infrastructure to improve the gathering of core data, such as how products are eventually disposed. The Department’s intention is to publish a roadmap later this year, to articulate our relevant findings and plans moving forward.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20866 question first answered 17/04/2024 14:13:08 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	411 label Biography information for Mr Barry Sheerman

1700047

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Alzheimer's Disease: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps she has taken to support research and development of the ACI-24 Alzheimer’s disease treatment.
	tabling member constituency	Romford
	tabling member printed	Andrew Rosindell
	uin	20911
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Department funds research through the National Institute for Health and Care Research (NIHR). The Government is strongly committed to supporting research into dementia, including Alzheimer’s disease treatment, and has committed to doubling funding for dementia research to £160 million per year, by the end of 2024/25.</p><p> </p><p>In addition, the NIHR’s infrastructure provides funding for clinical expertise, specialist facilities, the workforce, and support services, which underpin research across a range of clinical areas, including Alzheimer’s disease treatments. Specifically, the NIHR’s Oxford Health Clinical Research Facility (CRF) has enabled the delivery of the ABATE part 1 trial, which seeks to study the effects of the ACI-24 vaccine in those diagnosed with early-stage Alzheimer’s disease. The NIHR’s CRFs are purpose-built facilities for early-phase, experimental medicine, and supporting life science companies throughout the research process from study, design, data collection, and trial management.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/04/2024 11:07:46 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	1447 label Biography information for Andrew Rosindell

1700048

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer and Dementia: Research
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how much funding was provided for (a) dementia and (b) cancer research in the 2022-23 financial year.
	tabling member constituency	Romford
	tabling member printed	Andrew Rosindell
	uin	20912
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>Government responsibility for delivering dementia research and dementia research funding is shared between the Department of Health and Social Care, with research delivered by the National Institute for Health and Care Research (NIHR), and the Department for Science Innovation and Technology, with research delivered via UK Research and Innovation.</p><p>In 2022/23, we estimate that total Government spend on dementia research was £99.9 million, with £35.1 million of this being via the NIHR. The Department of Health and Social Care spends £1.3 billion per year on health research through the NIHR. NIHR research expenditure for all cancers was £121.8 million in 2022/23, and the NIHR spends more on cancer than any other disease group.</p><p>The NIHR funds research in response to proposals received from scientists rather than allocating funding to specific disease areas. The NIHR welcomes funding applications for research into any aspect of human health, including all cancers and dementia types. It is not usual practice to ring-fence funds for particular topics or conditions. Applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/04/2024 16:07:17 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	1447 label Biography information for Andrew Rosindell

1700068

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Trastuzumab Deruxtecan
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether NICE is taking steps to make Enhertu available to the National Health Service to treat incurable HER2-low secondary breast cancer.
	tabling member constituency	South Holland and The Deepings
	tabling member printed	Sir John Hayes
	uin	20865
	answer	answer is ministerial correction date of answer 16/04/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) is currently developing guidance for the National Health Service on whether Enhertu can be recommended for routine NHS funding, based on an assessment of the costs and benefits. The NICE was unfortunately unable to recommend Enhertu as a clinically and cost-effective use of NHS resources in its final draft guidance published on 5 March 2024. Stakeholders have had an opportunity to appeal against the NICE’s draft recommendations, and the NICE will consider any appeals through the established process, and will publish final guidance in due course.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/04/2024 15:03:45 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	350 label Biography information for Sir John Hayes

1700127

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Ambulance Services: Bullying and Discrimination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help tackle (a) sexism, (b) racism and (c) bullying behaviour within the ambulance service; and if she will establish an independent body to review complaints made by ambulance workers.
	tabling member constituency	Torridge and West Devon
	tabling member printed	Sir Geoffrey Cox
	uin	20936
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>Everyone working in the National Health Service must feel safe from any form of bullying, harassment, discrimination, or abuse, and feel confident that they can raise concerns, which will be taken seriously and acted on.</p><p> </p><p>The Department welcomes the publication of the NHS England commissioned independent review into ambulance sector culture. NHS England has established a Delivery Board to deliver the review’s important recommendations. This includes actions led by the Office of the Chief Allied Health Professions at NHS England, and the Association of Ambulance Chief Executives, on stopping misogyny and improving sexual safety in the ambulance service. This programme of work will build on the work already underway through the NHS People Plan, and the Equality, Diversity and Inclusion Improvement Plan</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/04/2024 11:05:58 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	1508 label Biography information for Sir Geoffrey Cox

1700141

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Bowel Cancer: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help improve genomics testing for bowel cancer patients.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	20972
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>A National Health Service testing programme is helping to diagnose thousands of people with a genetic condition, Lynch Syndrome, that increases the chance of developing certain cancers including bowel cancer. The national programme ensures all people diagnosed with bowel cancer are offered genomic testing, with a diagnosis for Lynch Syndrome not only helping to guide more personalised cancer treatment but enabling their families and relatives to be offered testing too. Relatives who receive a diagnosis of Lynch Syndrome can be referred to genetic services to discuss regular testing options to help catch any cancers as early as possible, as well as to consider preventive options such as taking aspirin or undergoing risk-reducing surgery.</p><p>Genomic testing in the NHS in England is provided through the NHS Genomic Medicine Service (GMS) and delivered by a national genomic testing network of seven NHS Genomic Laboratory Hubs (GLHs). The NHS GLHs deliver testing as directed by the National Genomic Test Directory (NGTD) which outlines the full range of genomic testing offered by the NHS in England including tests for 3,200 rare diseases and over 200 cancer clinical indications, including both whole genome sequencing (WGS) and non-WGS testing. The NGTD sets out the eligibility criteria for patients to access testing as well as the genomic targets to be tested and the method that should be used, including testing for bowel cancer patients.</p><p>The NHS GMS cancer genomic testing strategy has facilitated a move to a consolidated laboratory network through the seven NHS GLHs delivering more extensive panel testing using cutting edge high throughput Next Generation Sequencing (NGS) technology. For patients, including those with bowel cancer, this technology enables testing for a larger number of genetic variations to give a more precise diagnosis, identify biomarkers to target treatment and opportunities to access innovative medicines, and can support enrolment into molecularly stratified clinical trials.</p><p>Testing is available for all eligible patients across the whole of England. Individuals should discuss with their healthcare professional (for example, their general practitioner or other healthcare professional if they are already being seen in a relevant service) whether genomic testing is appropriate for them. Their healthcare professional will then make a decision whether to refer the individual either directly or via an NHS clinical genomics service or other relevant clinical speciality for genomic testing following clinical review of their and their family’s medical history if known, and the relevant genomic testing eligibility criteria.</p><p>The 17 NHS Clinical Genomic Services (NHS CGSs), commissioned by NHS England, deliver a comprehensive clinical genomic and counselling service that directs the diagnosis, risk assessment and lifelong clinical management of patients of all ages and their families who have, or are at risk of having, a rare genetic or genomic condition. As part of the NHS CGS, the patient and their family will access diagnosis, and management relevant to their particular condition, but also receive support and guidance so that they are able to understand their condition, its implications, and their options in relation to reproduction, screening, prevention and clinical management.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/04/2024 13:43:08 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3960 label Biography information for Henry Smith

1700146

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health Services: Standards
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether she plans to publish the results of the review by McKinsey and Co into NHS productivity.
	tabling member constituency	Ilford North
	tabling member printed	Wes Streeting
	uin	21154
	answer	answer is ministerial correction date of answer // answer text <p>The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered // answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4504 label Biography information for Wes Streeting